• Prohost Biotechnology. Biotech Blog, News and Comments. » Northwest Biotherapeutics (NWBO :OB)
  Barron’s believes that shares of Gilead Sciences (GILD) could soar 20 percent to 25 percent on strong demand for its existing AIDS and flu drugs as well as from new products in the pipeline. Why not if the earnings are climbing by double digit every yea
  in Public bookmarks with cancer gilead northwestbiotherapeutics research sciences treatment vaccine by 2 users

gilead from all users